Latest Breaking News On - Kyle gano - Page 2 : comparemela.com

Neurocrine, a regular name on Wall Street s M&A lists, elevates BD chief to succeed founder and CEO

Neurocrine, a regular name on Wall Street s M&A lists, elevates BD chief to succeed founder and CEO
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesMichel vounatsosSosei heptaresNeurocrine biosciencesKyle ganoChris viehbacherNxera pharmaKevin gormanTanabe pharmaXenon pharmaceuticalsDiurnal groupNeurocrine biosciencesEffective octoberWall streetNorth americanMitsubishi tanabe pharma

Neurocrine Biosciences Announces CEO Succession Plan

Neurocrine Biosciences Announces CEO Succession Plan
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKyle ganoLos angelesTanabe pharmaWilliamh rastetterNeurocrine biosciencesKylew ganoKevin gormanNxera pharmaSosei heptaresNeurocrine biosciences incUniversity of oregonFranchise teamEuropean unionIdorsia ltd

Brokerages Set Neurocrine Biosciences, Inc (NASDAQ:NBIX) PT at $137 92

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-three analysts that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average twelve-month target price among […]

United statesStifel nicolausKyle ganoNeurocrine biosciencesWilliamh rastetterNeurocrine biosciences incBenjaminf edwards company incJpmorgan chase coAcadian asset managementGoldman sachs groupEdgerock capitalLindbrook capitalSecurities exchange commissionNeurocrine biosciences company profileGet free reportExchange commission

Assenagon Asset Management S A Lowers Holdings in Neurocrine Biosciences, Inc (NASDAQ:NBIX)

Assenagon Asset Management S.A. lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 46.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 315,560 shares of the company’s stock after selling 268,979 shares during the quarter. Assenagon Asset Management […]

United statesNeurocrine biosciencesDarin lippoldtKyle ganoJpmorgan chase coRedhawk wealth advisors incCanaccord genuity groupLisanti capital growthSecurities exchange commissionNeurocrine biosciences incGuggenheim capitalFree reportWealth advisorsInvestment managementGet free reportExchange commission

Assenagon Asset Management S A Lowers Holdings in Neurocrine Biosciences, Inc (NASDAQ:NBIX)

Assenagon Asset Management S A Lowers Holdings in Neurocrine Biosciences, Inc (NASDAQ:NBIX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesNeurocrine biosciencesDarin lippoldtKyle ganoLisanti capital growthSecurities exchange commissionNeurocrine biosciences incGuggenheim capitalRedhawk wealth advisors incJpmorgan chase coCanaccord genuity groupFree reportWealth advisorsInvestment managementGet free reportExchange commission